GlaxoSmithKline has received the FDA’s approval for Lamictal ODT orally disintegrating tablets. Lamictal ODT uses a novel drug-delivery formulation to provide Lamictal in a tablet that has a
Swiss healthcare company Cardiola has received CE Mark recertification to market its m.pulse system for at-home use to treat chronic heart failure. Cardiola’s m.pulse system, based on Muscular
Acucela, a biotechnology company, has reported new safety, tolerability and effectiveness data on ACU-4429, an investigational therapy for dry age-related macular degeneration. According to Acucela, study participants tolerated
GlaxoSmithKline has agreed to extend its strategic relationship with Aspen Pharmacare Holdings and to acquire a 16% shareholding in the South African based pharmaceutical company. This is part
Highlights Total operating expenses increased $2,225 or less than 1% vs. the prior year’s comparable quarter. Operating loss for the quarter was $61,060 vs. $62,913 for the prior
Business Outlook and Guidance “We are confident about the prospects for our business in 2009 and will continue to focus on increasing market share by both strengthening and
Archimedes Pharma, a UK-based specialty pharmaceutical company, has reported new positive headline Phase III results for NasalFent, the company’s differentiated fentanyl citrate nasal spray, developed for the rapid
Daiichi Sankyo has reported blinded one-year blood pressure reduction data from the ongoing study Roadmap, the first-ever large-scale clinical trial, being conducted in 19 European countries to evaluate
Halozyme, a biopharmaceutical company, has reported a net loss of $14.72m, or $0.18 per share for the first quarter of 2009, compared to a net loss of $9.95m,
The PATH Malaria Vaccine initiative will provide funding, whereas scientists from the US National Institute of Allergy and Infectious Diseases (NIAID) will provide expertise to the project. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.